[
  {
    "ts": null,
    "headline": "Activist Glenview cuts stake in CVS after strong first-quarter earnings",
    "summary": "CVS shares have generated a total return of 25% since it took a position last year, suggesting progress in the company's turnaround plan, the hedge fund said.  It reduced its holdings by 3.75 million shares, just days after the healthcare conglomerate raised its annual forecast and beat Wall Street estimate for quarterly profit.  CVS had been facing pressure from investors, including Glenview, to improve its operations and shareholder value after missing financial targets several times due to increased medical costs in its health insurance business.",
    "url": "https://finnhub.io/api/news?id=31a9c130160a272b303b6a88f2679d35e43b6391a86d538b29fd7ae32a904988",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746564638,
      "headline": "Activist Glenview cuts stake in CVS after strong first-quarter earnings",
      "id": 134290353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS shares have generated a total return of 25% since it took a position last year, suggesting progress in the company's turnaround plan, the hedge fund said.  It reduced its holdings by 3.75 million shares, just days after the healthcare conglomerate raised its annual forecast and beat Wall Street estimate for quarterly profit.  CVS had been facing pressure from investors, including Glenview, to improve its operations and shareholder value after missing financial targets several times due to increased medical costs in its health insurance business.",
      "url": "https://finnhub.io/api/news?id=31a9c130160a272b303b6a88f2679d35e43b6391a86d538b29fd7ae32a904988"
    }
  },
  {
    "ts": null,
    "headline": "Glenview Capital Issues Statement on CVS Health",
    "summary": "One year ago, we established a concentrated position in shares of CVS Health (NYSE: CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company. Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan:",
    "url": "https://finnhub.io/api/news?id=55af2ae7846a63eeeea5e94d9dfc0bbf9201557f9bd36d3efc34102f12f5c866",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746562500,
      "headline": "Glenview Capital Issues Statement on CVS Health",
      "id": 134290354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "One year ago, we established a concentrated position in shares of CVS Health (NYSE: CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company. Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan:",
      "url": "https://finnhub.io/api/news?id=55af2ae7846a63eeeea5e94d9dfc0bbf9201557f9bd36d3efc34102f12f5c866"
    }
  },
  {
    "ts": null,
    "headline": "Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks",
    "summary": "I present 10 high-yield investment picks for May 2025, offering strong dividend income and growth potential. Read how investors can benefit from investing in stocks and ETFs.",
    "url": "https://finnhub.io/api/news?id=3e6d62be646e331485bd4a396e3b20a79dd3d571dab850af6ddc09933e402291",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746554400,
      "headline": "Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks",
      "id": 134278177,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148880312/image_2148880312.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "I present 10 high-yield investment picks for May 2025, offering strong dividend income and growth potential. Read how investors can benefit from investing in stocks and ETFs.",
      "url": "https://finnhub.io/api/news?id=3e6d62be646e331485bd4a396e3b20a79dd3d571dab850af6ddc09933e402291"
    }
  },
  {
    "ts": null,
    "headline": "HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down",
    "summary": "Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.",
    "url": "https://finnhub.io/api/news?id=b33e04348a19b18c53110be4790a79b959deff54cca919112a58289f37ecccd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746550800,
      "headline": "HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down",
      "id": 134290263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.",
      "url": "https://finnhub.io/api/news?id=b33e04348a19b18c53110be4790a79b959deff54cca919112a58289f37ecccd2"
    }
  },
  {
    "ts": null,
    "headline": "Activist investor Glenview Capital reduces stake in CVS Health",
    "summary": "Activist investor Glenview Capital said on Tuesday it reduced its holdings in CVS Health by 3.75 million shares after the insurer posted healthy first-quarter results and raised annual forecast. ...",
    "url": "https://finnhub.io/api/news?id=c916fcc6f7b6352985dbd7747159b5371c5942150ff5dd59a9500816d39b5969",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746550238,
      "headline": "Activist investor Glenview Capital reduces stake in CVS Health",
      "id": 134273177,
      "image": "",
      "related": "CVS",
      "source": "Finnhub",
      "summary": "Activist investor Glenview Capital said on Tuesday it reduced its holdings in CVS Health by 3.75 million shares after the insurer posted healthy first-quarter results and raised annual forecast. ...",
      "url": "https://finnhub.io/api/news?id=c916fcc6f7b6352985dbd7747159b5371c5942150ff5dd59a9500816d39b5969"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Corp. stock underperforms Tuesday when compared to competitors",
    "summary": "CVS Health Corp. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9a35ee42d6b94f216733e0beb126f160ff864eb28d128ae9a25a343e9bbf8524",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746549660,
      "headline": "CVS Health Corp. stock underperforms Tuesday when compared to competitors",
      "id": 134274796,
      "image": "",
      "related": "CVS",
      "source": "MarketWatch",
      "summary": "CVS Health Corp. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9a35ee42d6b94f216733e0beb126f160ff864eb28d128ae9a25a343e9bbf8524"
    }
  },
  {
    "ts": null,
    "headline": "INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts",
    "summary": "Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.",
    "url": "https://finnhub.io/api/news?id=2be65b216473fd9c44cfcec5a19a3558a411b05ddc611bef88c07448d25ec0a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746548940,
      "headline": "INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts",
      "id": 134290264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.",
      "url": "https://finnhub.io/api/news?id=2be65b216473fd9c44cfcec5a19a3558a411b05ddc611bef88c07448d25ec0a1"
    }
  },
  {
    "ts": null,
    "headline": "What Makes CVS Health (CVS) a New Buy Stock",
    "summary": "CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
    "url": "https://finnhub.io/api/news?id=1a8d9c1a0160e04fcf6a18dc67c4f7012ad0e8cd716cbf220bbfe603d3ede443",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746547210,
      "headline": "What Makes CVS Health (CVS) a New Buy Stock",
      "id": 134290357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
      "url": "https://finnhub.io/api/news?id=1a8d9c1a0160e04fcf6a18dc67c4f7012ad0e8cd716cbf220bbfe603d3ede443"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Value ESG Portfolios Q1 2025 Commentary",
    "summary": "While utilities typically perform well in volatile markets, our holdings in Edison International and Sempra were negatively impacted by the tragic wildfires in Southern California.",
    "url": "https://finnhub.io/api/news?id=b8d49119538f180c52c77ed415ef0caaf6f7b39d2626d0a871229c75cda36359",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746541740,
      "headline": "ClearBridge Large Cap Value ESG Portfolios Q1 2025 Commentary",
      "id": 134269144,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323554443/image_1323554443.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "While utilities typically perform well in volatile markets, our holdings in Edison International and Sempra were negatively impacted by the tragic wildfires in Southern California.",
      "url": "https://finnhub.io/api/news?id=b8d49119538f180c52c77ed415ef0caaf6f7b39d2626d0a871229c75cda36359"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?",
    "summary": "Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged.  The company's GLP-1 drugs continue to drive strong revenue growth.  Mounjaro is approved by the Food and Drug Administration (FDA) to help adults with type 2 diabetes lower their blood glucose levels, while Zepbound is approved for weight loss in obese adults or overweight adults with at least one weight-related condition, such as high cholesterol or high blood pressure.",
    "url": "https://finnhub.io/api/news?id=3a2060c30b03646ef801c332a812ff0589a290bbcec367fe4544109ae49a65c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746540000,
      "headline": "Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?",
      "id": 134266214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged.  The company's GLP-1 drugs continue to drive strong revenue growth.  Mounjaro is approved by the Food and Drug Administration (FDA) to help adults with type 2 diabetes lower their blood glucose levels, while Zepbound is approved for weight loss in obese adults or overweight adults with at least one weight-related condition, such as high cholesterol or high blood pressure.",
      "url": "https://finnhub.io/api/news?id=3a2060c30b03646ef801c332a812ff0589a290bbcec367fe4544109ae49a65c4"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?",
    "summary": "The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=199b85c4b9d8261fce8be8ef2917dbbab7a4b400fac2abaf5cb1e13a5408d640",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746538208,
      "headline": "Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?",
      "id": 134266632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=199b85c4b9d8261fce8be8ef2917dbbab7a4b400fac2abaf5cb1e13a5408d640"
    }
  },
  {
    "ts": null,
    "headline": "Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?",
    "summary": "Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=6713227b7d3118ff51745ca579af4efb7b2c24ed82c2bacfbc3a60aa99e446e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746536414,
      "headline": "Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?",
      "id": 134266633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=6713227b7d3118ff51745ca579af4efb7b2c24ed82c2bacfbc3a60aa99e446e4"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Value Discovery Fund Q1 2025 Commentary",
    "summary": "For Q1 2025, Fidelity Value Discovery Fund gained 2.16%, outpacing the 1.64% advance of the benchmark Russell 3000Â® Value Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=53375086f9e69202cd0804bd81b8e63e7fed94f88af93af7eccc90ff8c1bb07a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746526800,
      "headline": "Fidelity Value Discovery Fund Q1 2025 Commentary",
      "id": 134265479,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1490285173/image_1490285173.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, Fidelity Value Discovery Fund gained 2.16%, outpacing the 1.64% advance of the benchmark Russell 3000Â® Value Index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=53375086f9e69202cd0804bd81b8e63e7fed94f88af93af7eccc90ff8c1bb07a"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Portfolios Q1 2025 Commentary",
    "summary": "Amid a tech-led selloff, the benchmark Russell 1000 Value Index (+2.1%) handily outperformed its growth counterpart (-10.0%) in the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=813a45b68433dfd9e6d78470049b96bfe8627789fe62da3ab961f339479d7afe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746525600,
      "headline": "ClearBridge Value Portfolios Q1 2025 Commentary",
      "id": 134265358,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1934575967/image_1934575967.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "Amid a tech-led selloff, the benchmark Russell 1000 Value Index (+2.1%) handily outperformed its growth counterpart (-10.0%) in the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=813a45b68433dfd9e6d78470049b96bfe8627789fe62da3ab961f339479d7afe"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Value Portfolios Q1 2025 Commentary",
    "summary": "ClearBridge Large Cap Value Portfolios Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=a8a34f633350da1dc409f7f5ba35c4344fb908b49369a5843f610121d8e3ce10",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746514260,
      "headline": "ClearBridge Large Cap Value Portfolios Q1 2025 Commentary",
      "id": 134260408,
      "image": "",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a8a34f633350da1dc409f7f5ba35c4344fb908b49369a5843f610121d8e3ce10"
    }
  }
]